We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

N4 Pharma plc (N4P) ORD GBP0.004

Sell:0.70p Buy:0.75p 0 Change: 0.1p (16.00%)
Market closed |  Prices as at close on 4 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.70p
Buy:0.75p
Change: 0.1p (16.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 4 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.70p
Buy:0.75p
Change: 0.1p (16.00%)
Market closed |  Prices as at close on 4 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.

Contact details

Address:
Weston House, 1 Bradgate Park View
DERBY
DE73 5UJ
United Kingdom
Telephone:
+44 (01332) 690061
Website:
https://www.n4pharma.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 24 September 2024 24/09/24
AGM 23 May 2024 23/05/24
Annual report 29 April 2024 29/04/24
Final results 23 April 2024 23/04/24

General stock information

EPIC:
N4P
ISIN:
GB00BYW8QM32
Market cap:
£2.86 million
Shares in issue:
394.78 million
Sector:
Software & Computer Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Nigel Theobald
    Chief Executive Officer, Executive Director
  • Luke Cairns
    Executive Director
  • David Templeton
    Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.